02/09/2014 22:20:24 Free Membership Login

Xoma News (NASDAQ:XOMA)

DateTimeSource
Headline
05/09/20144:00PMZACKSXOMA Posts Wider Q1 Loss - Analyst Blog
XOMA Corporation’s (XOMA) shares declined 18.5% after the company reported wider-than-expected loss per share in the first quarter of 2014 and slower-than-expected patient enrolment in two phase III studies being conducted with gevokizumab. The company posted a loss of 23 cents per share, wider than the Zacks Consensus... More...>>
03/19/20148:00AMPRNUSHealthcare Companies Report Financial Results, Partnerships, and Recognitions - Analyst Notes on Keryx, WellCare, Zogenix, Or...
Healthcare Companies Report Financial Results, Partnerships, and Recognitions - Analyst Notes on Keryx, WellCare, Zogenix, Orexigen Therapeutics, and XOMA Editor Note: For more information about this release, please scroll to bottom. PR Newswire NEW YORK, March 19, 2014 NEW YORK, March 19, 2014 /PRNewswire/ -- Today, Analysts... More...>>
03/06/201412:22PMPRNUSTechnical Roundup - Most Active: J. C. Penney, XOMA, BlackBerry and Nokia
Technical Roundup - Most Active: J. C. Penney, XOMA, BlackBerry and Nokia PR Newswire NEW YORK, March 6, 2014 NEW YORK, March 6, 2014 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. The trading session on Wednesday, March 05, 2014 ended on a mixed note as the Dow Jones Industrial... More...>>
01/14/20148:52AMZACKSSurging Earnings Estimates Signal Good News for XOMA Corporation (XOMA) - Tale of the Tape
Xoma Corporation (XOMA) is a developer of antibody-based therapeutics that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well. These positive earnings estimate revisions suggest... More...>>
12/03/20134:28AMZACKSPharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook
With 2013 coming to an end, the worst of the patent cliff faced by the pharmaceutical sector is over. Major blockbuster drugs like Merck’s (MRK) Singulair, Pfizer’s (PFE) Lipitor, Forest Laboratories’ (FRX) Lexapro, Sanofi/Bristol-Myers Squibbs’ (SNY/BMY) Plavix and Eli Lilly’s (LLY) Zyprexa... More...>>
12/03/20134:28AMZACKSPharma & Biotech Stock Outlook - Dec 2013 - Zacks Analyst Interviews
With 2013 coming to an end, the worst of the patent cliff faced by the pharmaceutical sector is over. Major blockbuster drugs like Merck’s (MRK) Singulair, Pfizer’s (PFE) Lipitor, Forest Laboratories’ (FRX) Lexapro, Sanofi/Bristol-Myers Squibbs’ (SNY/BMY) Plavix and Eli Lilly’s (LLY) Zyprexa... More...>>
12/03/20134:28AMZACKSPharma & Biotech Stock Outlook - Dec 2013 - Zacks Analyst Interviews
With 2013 coming to an end, the worst of the patent cliff faced by the pharmaceutical sector is over. Major blockbuster drugs like Merck’s (MRK) Singulair, Pfizer’s (PFE) Lipitor, Forest Laboratories’ (FRX) Lexapro, Sanofi/Bristol-Myers Squibbs’ (SNY/BMY) Plavix and Eli Lilly’s (LLY) Zyprexa... More...>>
12/03/20134:28AMZACKSPharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook
With 2013 coming to an end, the worst of the patent cliff faced by the pharmaceutical sector is over. Major blockbuster drugs like Merck’s (MRK) Singulair, Pfizer’s (PFE) Lipitor, Forest Laboratories’ (FRX) Lexapro, Sanofi/Bristol-Myers Squibbs’ (SNY/BMY) Plavix and Eli Lilly’s (LLY) Zyprexa... More...>>
12/03/20134:28AMZACKSPharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook
With 2013 coming to an end, the worst of the patent cliff faced by the pharmaceutical sector is over. Major blockbuster drugs like Merck’s (MRK) Singulair, Pfizer’s (PFE) Lipitor, Forest Laboratories’ (FRX) Lexapro, Sanofi/Bristol-Myers Squibbs’ (SNY/BMY) Plavix and Eli Lilly’s (LLY) Zyprexa... More...>>
11/15/20138:39AMDJNKingdon Capital Management 3Q 13F: Largest Purchases
DJ CFA SOURCE: SEC 13F-HR FILER: Kingdon Capital Management LLC QUARTER ENDED: 09/30/2013 SEC RECEIVED: 11/14/2013 Up to 200 of the largest purchases of Kingdon Capital Management LLC are listed below, ordered by the number of shares bought during the three months ended Sep. 30. Company Name Value Holdings Change CANADIAN... More...>>
11/15/20138:39AMDJNKingdon Capital Management 3Q 13F: Holdings As Of -2-
OWENS CORNING COM $1,899,000 50,000 50,000 * KOHLS CORP COM $1,811,250 35,000 35,000 * ENANTA PHARMACEUTICALS INC CO $1,719,000 75,000 0 ISHARES MSCI MEXICO CAPPED ETF $1,597,250 25,000 25,000 * STRYKER CORP COM $1,514,016 22,400 0 SOLAZYME INC COM $1,314,152 121,850 0 IMPAX LABORATORIES INC COM $1,125,850 55,000 (105,000... More...>>
11/15/20138:39AMDJNKingdon Capital Management 3Q 13F: Holdings As Of Sep 30
DJ CFA SOURCE: SEC 13F-HR FILER: Kingdon Capital Management LLC QUARTER ENDED: 09/30/2013 SEC RECEIVED: 11/14/2013 The following sets forth up to 200 of the largest holdings of Kingdon Capital Management LLC as of Sep. 30, according to a Form 13F filed with the Securities and Exchange Commission. As of Sep. 30, Kingdon... More...>>
11/15/20138:22AMDJNJanus Capital Management 3Q 13F: Largest Purchases -2-
STANDARD PARKING CORP COM $55,745,955 2,073,111 37,128 RED HAT INC COM $9,827,912 213,002 33,229 ICICI BANK LTD ADR $1,962,912 64,400 31,713 W W GRAINGER INC COM $206,623,447 789,513 30,944 SYNAGEVA BIOPHARMA CORP COM $79,011,155 1,246,390 29,468 BBVA BANCO FRANCES SA ADR $192,953 29,103 29,103 CTPARTNERS EXECUTIVE SEARCH... More...>>
11/15/20138:22AMDJNJanus Capital Management 3Q 13F: Largest Purchases
DJ CFA SOURCE: SEC 13F-HR FILER: Janus Capital Management LLC QUARTER ENDED: 09/30/2013 SEC RECEIVED: 11/14/2013 Up to 200 of the largest purchases of Janus Capital Management LLC are listed below, ordered by the number of shares bought during the three months ended Sep. 30. Company Name Value Holdings Change ORACLE CORP... More...>>
11/14/20137:19AMDJNThe Vanguard Group 3Q 13F: Largest Purchases -2-
DOLLAR GENERAL CORP COM $992,795,576 17,584,052 1,114,471 AGL RESOURCES INC COM $426,410,182 9,263,745 1,103,235 PIER 1 IMPORTS INC COM $108,256,866 5,545,946 1,101,639 SCHLUMBERGER NV COM $5,724,029,809 64,780,781 1,099,740 LAS VEGAS SANDS CORP COM $940,923,853 14,166,273 1,078,054 LEVEL 3 COMMUNICATIONS INC CO $260,802,990... More...>>
11/14/20137:19AMDJNThe Vanguard Group 3Q 13F: Largest Sales
DJ CFA SOURCE: SEC 13F-HR FILER: The Vanguard Group, Inc. QUARTER ENDED: 09/30/2013 SEC RECEIVED: 11/07/2013 Up to 200 of the largest sales of The Vanguard Group, Inc. are listed below, ordered by the number of shares sold during the three months ended Sep. 30. Company Name Value Holdings Change SIRIUS XM RADIO INC COM... More...>>
07/05/20134:39PMZACKSSymplmed Wins Rights from XOMA - Analyst Blog
XOMA Corporation (XOMA) recently announced that it has entered into an agreement with Symplmed Pharmaceuticals, LLC (founded by some ex- XOMA employees) to transfer the US development and marketing rights to the perindopril franchise to the latter. In exchange, XOMA will get a stake in Symplmed. We note that the perindopril... More...>>
06/26/20138:30AMIHNWVIP EARLY ALERT SERVICE Offered by Elite Traders Group for Limited Time, 11 Positions Remain. Only $29.95/Month or $199.00/Year
One of the most frequently asked questions is, "does your VIP group receive alerts ahead of the crowd?" and the answer is YES. We offer our VIP's early alerts and VIP only alerts that the rest of the group is not privy to. VIP early alerts and VIP only alerts are provided via our private VIP twitter feed which is not viewable... More...>>
05/09/201312:00PMZACKSPositive Data on Celgene's Apremilast - Analyst Blog
Celgene Corporation (CELG) recently announced positive results from the PALACE 4 study on apremilast. The study is evaluating apremilast (20 mg and 30 mg), a novel, oral small-molecule inhibitor of phosphodiesterase 4 (PDE4), in patients suffering from psoriatic arthritis. Results from the phase III study showed that apremilast... More...>>
05/09/201311:50AMZACKSARNA Sheds Light on Belviq Launch - Analyst Blog
Arena Pharmaceuticals Inc. (ARNA) recently announced that the US Drug Enforcement Administration (DEA) has assigned its obesity drug Belviq into Schedule IV of the Controlled Substances Act. The company expects to make Belviq available in the US in a month. Upon commercialization of Belviq, Arena Pharma will receive $65... More...>>


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 us nasdaq xoma140902 22:20